Abstract
The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern Germany) and the excellence research program ONKOTHER-H (Rostock/Greifswald, Germany). The meeting showcased cutting-edge research and liberated discussions on the application of therapeutic ROS and immunology in cancer treatment, primarily focusing on gas plasma technology. The 2-day hybrid meeting took place in Greifswald and online from 15–16 July 2021, facilitating a wide range of participants totaling 66 scientists from 12 countries and 5 continents. The meeting aimed at bringing together researchers from a variety of disciplines, including chemists, biochemists, biologists, engineers, immunologists, physicists, and physicians for interdisciplinary discussions on using therapeutic ROS and medical gas plasma technology in cancer therapy with the four main sessions: “Plasma, Cancer, Immunity”, “Plasma combination therapies”, “Plasma risk assessment and patients studies”, and “Plasma mechanisms and treated liquids in cancer”. This conference report outlines the abstracts of attending scientists submitted to this meeting.
Highlights
Reactive oxygen species (ROS) have critical functions in cell signaling, cell damage, immune response, and diseases
The first Therapeutic ROS and Immunity in Cancer (TRIC) meeting was organized by the excellence research center ZIK plasmatis (with its previous Frontiers in Redox Biochemistry and Medicine (FiRBaM) and Young Professionals’ Workshop in Plasma Medicine (YPWPM) workshop series in Northern
We investigated the effects of atmospheric-pressure cold plasma-generated short-lived species, long-lived species, and electric fields on skin cancer cells and normal cells (BJ cells, Detroit cells)
Summary
Reactive oxygen species (ROS) have critical functions in cell signaling, cell damage, immune response, and diseases. While the atmospheric pressure argon plasma jet kINPen MED (neoplas MED GmbH, Greifswald, Germany) has already entered small-scale clinical studies in oncology and for treating dozens of precancerous and cancerous lesions in hundreds of treatment sessions thanks to the passion of two key medical doctors in the field of plasma oncology, Hans-Robert Metelmann and Christian Seebauer, there are new initiatives at the horizon in Canada and the U.S to promote this route with other jet-based devices further To this end, the safety and risk assessment session of our meeting was a significant contribution to such considerations.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
